home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Antibody Has Therapeutic Effect on Mice with ALS

  April, 9 2010 9:21
your information resource in human molecular genetics

A biological treatment targeting the protein CD40L has a therapeutic effect on mice with amyotrophic lateral sclerosis (ALS), reports a new study published in Nature Genetics. The study suggests that ALS progression may be amenable to treatments that target the immune response.

ALS is a progressive neurodegenerative disease that leads to neuron loss in the brain and spinal cord and eventual paralysis. ALS affects approximately 2 per 100,000 individuals worldwide and is typically fatal within 5 years of diagnosis.

Steven Perrin and colleagues administered a monoclonal antibody to CD40L to mice with a mutation in SOD1 -- a commonly used mouse model for ALS. They found that the anti-CD40L antibody delayed onset of paralysis and on average, led to a 40% extension of life duration after the first signs of paralysis.

Author contact:

Steven Perrin (ALS Therapy Development Institute, Cambridge, MA, USA)
E-mail: sperrin@als.net

Abstract available online.

(C) Nature Genetics press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.